Stereotactic radiotherapy for pulmonary metastases.

Published

Journal Article (Review)

The most common treatment of pulmonary metastasis for solid tumors employs systemic chemotherapy, hormonal therapy, or biologic agents. Some series have suggested that aggressive surgical resection of pulmonary metastasis may improve patient outcomes in terms of quality of life and overall survival. Recently, data from clinical trials and retrospective series support the use of aggressive local control with high conformal dose radiotherapy (stereotactic body radiation therapy) in patients with limited metastases or oligometastases. Further evidence suggests that these patients represent a distinct clinical and biological class of patients. This review focuses on the role of ablative doses of radiotherapy in the treatment of pulmonary metastases. Specifically we discuss the rationale, treatment delivery, and local control that have led to the ongoing randomized clinical trials attempting to demonstrate a benefit over the current palliative standard of care.

Full Text

Duke Authors

Cited Authors

  • Chmura, SJ; Salama, JK; Weichselbaum, RR

Published Date

  • 2013

Published In

Volume / Issue

  • 25 / 4

Start / End Page

  • 292 - 299

PubMed ID

  • 24673958

Pubmed Central ID

  • 24673958

Electronic International Standard Serial Number (EISSN)

  • 1532-9488

Digital Object Identifier (DOI)

  • 10.1053/j.semtcvs.2014.01.003

Language

  • eng

Conference Location

  • United States